Journal of Antimicrobial Chemotherapy (2002) 49, 243-253
© 2002 The British Society for Antimicrobial Chemotherapy
The 2001 Garrod Lecture |
The treatment of cytomegalovirus infection
Department of Virology, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill Street, London NW3 2PF, UK
This named lecture provides an opportunity to take an historical perspective on cytomegalovirus (CMV) infection. A major theme will be that modern molecular biological research has questioned the conventional wisdom that CMV is a slow-growing virus, which only damages a few individuals. I will first review details of the genetic constitution of the virus, emphasizing that wild strains contain many genes which are missing from their laboratory-adapted cousins. I will then review the diseases associated with CMV, not just the end-organ diseases of pneumonitis/retinitis, etc., but the so-called indirect effects, including graft rejection, secondary microbial infections and accelerated atherosclerosis. The urgent need for safe and potent antiviral drugs to prevent these diseases will be considered in two ways: first, the failure of the conventional drug discovery approach; and secondly, the opportunities offered by targeting novel gene functions. The controlled clinical trials performed to date will be summarized, together with suggestions about pharmacodynamic evaluations in the future.
* *Tel: +44-20-7830-2997; Fax: +44-20-7830-2854; E-mail: p.griffiths{at}rfc.ucl.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. M. Kotloff, V. N. Ahya, and S. W. Crawford Pulmonary Complications of Solid Organ and Hematopoietic Stem Cell Transplantation Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 22 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Wang, R. W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M. B. Wire Phase I Safety and Pharmacokinetic Trials of 1263W94, a Novel Oral Anti-Human Cytomegalovirus Agent, in Healthy and Human Immunodeficiency Virus-Infected Subjects Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1334 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Crowley Ganciclovir treatment of symptomatic congenital cytomegalovirus infection J. Antimicrob. Chemother., September 1, 2002; 50(3): 435 - 436. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Koszalka, N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain, L. B. Townsend, J. C. Drach, and K. K. Biron Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2373 - 2380. [Abstract] [Full Text] [PDF]
|
|